Colgate-Palmolive Company
—- Market cap
- $70.07B
- Debt
- —
- Cash
- −$1.29B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CL stock price at premium vs GILD $87.90 current versus $56.17 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Implied fair value · at CL's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CL vs PG
JOHNSON & JOHNSON
CL vs JNJ
CHURCH & DWIGHT CO INC /DE/
CL vs CHD
KIMBERLY CLARK CORP
CL vs KMB
EDGEWELL PERSONAL CARE Co
CL vs EPC
UNILEVER PLC
CL vs UL
AbbVie Inc.
CL vs ABBV
AMGEN INC
CL vs AMGN
BRISTOL MYERS SQUIBB CO
CL vs BMY
Merck & Co., Inc.
CL vs MRK
PFIZER INC
CL vs PFE
REGENERON PHARMACEUTICALS, INC.
CL vs REGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CL can sustain a premium P/E despite weaker margins and higher leverage, then hold or add selectively; otherwise, reduce exposure because the current price implies substantial downside versus the $51.67 P/E-derived value and the DCF range is far below spot.
CL trades at a significant premium on earnings versus GILD, with a P/E of 35.5x versus 19.6x, yet the implied price is 44.6% below the current price of $93.27. The gap is harder to justify because CL also lags GILD on profitability and growth in most operating metrics.
Supporting Metrics